PATENT COOPERATION TRATTY



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

	icant's		ent's file reference 01	FOR FURTHER A	CTION		n of Transmittal of International amination Report (Form PCT/PEA/416)
1	nationa		ication No. 676	International filing date 06.08.2003	(day/mon	th/year)	Priority date (day/month/year) 10.08.2002
₹	nationa 7D401		nt Classification (IPC) or I	both national classification	and IPC		
1	icant FANA	PHA	RMA AG				
1.	This Auth	interi ority	national preliminary exa		en prepa Article 3	red by this Inte 6.	rnational Preliminary Examining
2.	This	REP	ORT consists of a total	of 5 sheets, including t	his cove	r sheet.	
		beer	n amended and are the		d <i>l</i> or shee	ts containing r	on, claims and/or drawings which have ectifications made before this Authority the PCT).
	Thes	se anı	nexes consist of a total	of sheets.			
3.	This	repoi	rt contains indications r	elating to the following i	tems:		
	1		Basis of the opinion	3			
į	i.		Priority				
Ì	111	⊠		f opinion with regard to r	noveltv. i	nventive step a	and industrial applicability
	١V		Lack of unity of inven		ioroky,		The Production approaching
	٧	Ø	Reasoned statement				ventive step or industrial applicability;
	VI		Certain documents cl	ited			·
1	VII		Certain defects in the	international application	n		
	VIII		Certain observations	on the International app	lication		
<u></u>					T		
Date	of sub	missio	on of the demand		Date of	completion of th	is report
17.0	02.20	04			16.04	.2004	
			g address of the internatio	nal	Authori	zed Officer	
	<u>g</u>))	Eu D-8 Tel	ropean Patent Office 30298 Munich I. +49 89 2399 - 0 Tx: 523 x: +49 89 2399 - 4465	656 epmu d	'	kakou, G one No. +49 89 2	2399-7835

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP 03/08676

i. B	asis	of t	the	rep	ort
------	------	------	-----	-----	-----

1. With regard to the **elements** of the international application (Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)):

	Des	cription, Pages	
	1-29	e	as originally filed
	Clai	ims, Numbers	
	1-17		as originally filed
2.	Witl lang	n regard to the langua guage in which the inte	age, all the elements marked above were available or furnished to this Authority in the ernational application was filed, unless otherwise indicated under this item.
	The	se elements were ava	ailable or furnished to this Authority in the following language: , which is:
		the language of a tra	nslation furnished for the purposes of the international search (under Rule 23.1(b)).
		the language of publ	ication of the international application (under Rule 48.3(b)).
		the language of a tra Rule 55.2 and/or 55.5	nslation furnished for the purposes of International preliminary examination (under 3).
3.	With inte	n regard to any nucle rnational preliminary (otide and/or amino acid sequence disclosed in the international application, the examination was carried out on the basis of the sequence listing:
		contained in the inter	national application in written form.
		filed together with the	e international application in computer readable form.
		furnished subsequer	tly to this Authority in written form.
		furnished subsequen	tly to this Authority in computer readable form.
			ne subsequently furnished written sequence listing does not go beyond the disclosure oplication as filed has been furnished.
-		The statement that the listing has been furni	ne information recorded in computer readable form is identical to the written sequence shed.
4.	The	amendments have re	esulted in the cancellation of:
		the description,	pages:
		the claims,	Nos.:
		the drawings,	sheets:
5.		This report has been been considered to g	established as if (some of) the amendments had not been made, since they have to beyond the disclosure as filed (Rule 70.2(c)).
		(Any replacement sh report.)	eet containing such amendments must be referred to under item 1 and annexed to th
6.	Add	litional observations, i	f necessary:

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP 03/08676

•••	. 110	restablishment of opinion w	ritir i e	gard to nove	my, inventive step and inclustrial applicability
1.	The obv	e questions whether the claime rious), or to be industrially appl	d invei icable	ntion appear have not bee	s to be novel, to involve an inventive step (to be non- en examined in respect of:
		the entire international applica	ation,		
	Ø	claims Nos. 16 and 17 in resp	ect of	industrial ap	plicability
		because:			
		the said international application not require an international property of the said international property of the said international applications.	ion, or elimina	the said clai ary examinat	ns Nos. relate to the following subject matter which does on (specify):
		the description, claims or draw that no meaningful opinion co	vings (uld be	<i>(indicate part</i> formed <i>(spe</i>	icular elements below) or said claims Nos. are so unclear cify):
		the claims, or said claims Noscould be formed.	s. are s	o inadequate	sly supported by the description that no meaningful opinion
		no international search report	has b	een establish	ed for the said claims Nos.
2.	or a	eaningful international prelimir mino acid sequence listing to o ructions:	nary ex comply	camination ca with the star	nnot be carried out due to the failure of the nucleotide and and address of the Administrative
		the written form has not been	furnist	ned or does r	not comply with the Standard.
		the computer readable form h	as not	been fürnish	ed or does not comply with the Standard.
٧.	Rea cita	soned statement under Artic tions and explanations supp	ele 35(orting	2) with rega such state	rd to novelty, inventive step or industrial applicability; nent
1.	Stat	rement			
	Nov	elty (N)	Yes: No:	Claims Claims	1-17
	Inve	entive step (IS)	Yes:	Claims	1-17

No:

No:

Claims

Claims

1-15

Yes: Claims

2. Citations and explanations

Industrial applicability (IA)

see separate sheet

EXAMINATION REPORT - SEPARATE SHEET

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 16 and 17 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Cited Documents

1.1. Certain published documents (Rule 70.10)

WO-A-02085906 (=D1)

WO-A-02064584 (=D2)

1.2 Reference is made to the following Documents.

WO-A-0130777 (=D3)

WO-A-9931090 (=D4)

WO-A-9931071 (=D5)

WO-A-9831674 (=D6)

WO-A-9307146 (=D7)

J.Med. Chem. 2001,44,2523 (=D8)

J.Med. Chem. 2002,45,2520 (=D9)

J.Med. Chem. 2002,45,2526 (=D10)

The indicated designation is used throughout the examination procedure

3. Novelty

The present application and the prior art Documents D3-D10 relate to 2-N-substitutedpyridazinones. The main structural difference resides in the nature of the "-Nsubstituent.

The subject matter of the present claims 1-17 can therefore be considered to be novel.

4. Inventive step

INTERNATIONAL PRELIMINARY International application No. PCT/EP03/08676

EXAMINATION REPORT - SEPARATE SHEET

- **4.1** The object of the present invention is to provide compounds useful as PDE4 inhibitorss.
- **4.2** In the light of the pharmacological tests comprised in the Description (28-29) it is considered as credible that a limited number of the claimed compounds have the alleged activity.
- 4.3 The prior art documents D3-D10 which disclose structurally similar pyridazinone derivatives having PDE4 inhibitory activity are considered to be especially relevant. With respect to the said prior art documents the main structural difference lies in the modification of the 2N--substituent of the pyridazinone. Taking the above into account it is evident for the person skilled in the art that the pyridazinone group is fundamental for the PDE4 Inhibitory activity and further modification of the substituents results to more or less potent agents while the PDE4 inhibitory activity is maintained. The claimed compounds are therefore considered to be prima facie obvious and an inventive step cannot be acknowledged,

		PCT/EP	03/08676
A. CLASS IPC 7	RIFICATION OF SUBJECT MATTER C07D401/04 C07D405/14 A61K31/	50	
According	to International Patent Classification (IPC) or to both national classifi	cation and IPC	
	SSEARCHED		
Minimum d IPC 7	tocumentation searched (classification system followed by classification ${\tt C07D}$	tion symbols)	
Documenta	ation searched other than minimum documentation to the extent that	such documents are included in the fie	elds searched
Electronic	data base consulted during the International search (name of data b	ase and, where practical, search terms	s used)
EPO-Ir	nternal, WPI Data, PAJ, CHEM ABS Dat	a	
	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the re-	elevant passages	Relevant to claim No.
P,A	WO 02 085906 A (ALTANA PHARMA AG 31 October 2002 (2002-10-31) cited in the application page 31 -page 41; claims 1-13	1–17	
P,A	WO 02 064584 A (BYK GULDEN LOMBE CHEMISCHE FABRIK GMBH) 22 August 2002 (2002-08-22) cited in the application page 25 -page 36; claims 1-13	1–17	
Y	WO 99 31090 A (BYK GULDEN LOMBER CHEMISCHE FABRIK GMBH) 24 June 1999 (1999-06-24) cited in the application page 34 -page 38; claims 1-10	G	1–17
		-/	
X Fur	ther documents are listed in the continuation of box C.	X Patent family members are	listed in annex.
° Special c	ategories of cited documents :	*T* later document published after th	e international filing date
consi "E" earlier	ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international	or priority date and not in conflic cited to understand the principle invention 'X' document of particular relevance	or theory underlying the
which citatio	cale ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another in or other special reason (as specified) hent referring to an oral disclosure, use, exhibition or	cannot be considered novel or o involve an Inventive step when i "Y" document of particular relevance cannot be considered to involve	annot be considered to the document is taken alone ; the claimed invention an inventive step when the
other 'P' docum	means included prior to the international filling date but than the priority date claimed	document is combined with one ments, such combination being in the art. *&" document member of the same p	obvious to a person skilled
Date of the	actual completion of the international search	Date of mailing of the internation	nal search report
2	24 November 2003	12/12/2003	
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk	Authorized officer	
	Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Kyriakakou, G	



Internal Application No PCT/EP 03/08676

Category *	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
eredory 2	Oralion of document, with indication,where appropriate, of the relevant passages	Helevant to claim No.
,	WO 01 30777 A (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH) 3 May 2001 (2001-05-03) cited in the application page 21 -page 25; claims 1-10	1-17
'	WO 99 31071 A (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH) 24 June 1999 (1999-06-24) cited in the application page 32 -page 36; claims 1-10	1–17
Y	WO 98 31674 A (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH) 23 July 1998 (1998-07-23) cited in the application page 49 -page 55; claims 1-10	1-17
Υ	WO 93 07146 A (SYNTEX INC.) 15 April 1993 (1993-04-15) cited in the application page 162 -page 169; claims 1-33	1-17
Y	MARGARETHA VAN DER MEY ET AL.: "Novel Selective Phosphodiesterase (PDE4) inhibitors. 4. Resolution, Absolute Configuration and PDE4 Inhibitory Activity of cis-Tetra- and cis-Hexahydrophathalazinones" JOURNAL OF MEDICINAL CHEMISTRY., vol. 45, no. 12, 6 June 2002 (2002-06-06), pages 2526-2533, XP002262562 AMERICAN CHEMICAL SOCIETY., US ISSN: 0022-2623 cited in the application the whole document	1-17
Y	MARGARETHA VAN DER MEY ET AL.: "Novel Selective PDE4 Inhibitors.3. In Vivo Antiinflammatory Activity of a New Series of N-Substituted cis-Tetra- and cis-Hexahydrophthalazinones" JOURNAL OF MEDICINAL CHEMISTRY., vol. 45, no. 12, 6 June 2002 (2002-06-06), pages 2520-2525, XP002262563 AMERICAN CHEMICAL SOCIETY., US ISSN: 0022-2623 cited in the application the whole document	1-17
	,	
	·	
		1





C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT						
alegory °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.				
	MARGARETHA VAN DER MEY ET AL.: "Novel Selective PDE4 Inhibitors. 2. Synthesis and Structure-Activity Relationships of 4-Aryl-Substituted cis-Tetra- and Cis-Hexahydrophthalazinones" JOURNAL OF MEDICINAL CHEMISTRY., vol. 44, no. 16, 2 August 2001 (2001-08-02), pages 2523-2535, XP002222951 AMERICAN CHEMICAL SOCIETY., US ISSN: 0022-2623 cited in the application the whole document	1-17				



INTERNATIONAL SEARCH REPORT

International application No. PCT/EP 03/08676

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This inter	mational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
t t	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Although claims 16 and 17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged
2	effects of the compound/composition. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II (Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This Interr	national Searching Authority found multiple inventions in this international application, as follows:
1. A	As all required additional search fees were timely pald by the applicant, this international Search Report covers all searchable daims.
2. A	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. A	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. N	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is estricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark or	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.



Internal Application No
PCT/EP 03/08676

					017 21	03/080/0
Patent docume clted in search re		Publication date		Patent family member(s)		Publication date
WO 0208590	6 A	31-10-2002	WO	02085906	A2	31-10-2002
WO 0206458	4 A	22-08-2002	CA EE WO EP	2438520 200300311 02064584 1362044	A A1	22-08-2002 15-10-2003 22-08-2002 19-11-2003
WO 9931090	A	24-06-1999	AU AU CA EE WO EP HU JP PL US	753576 2270199 2314111 200000335 9931090 1042319 0004561 2002508368 341239 6380196	A A1 A1 A1 A2 T A1	24-10-2002 05-07-1999 24-06-1999 15-10-2001 24-06-1999 11-10-2000 28-03-2002 19-03-2002 26-03-2001 30-04-2002
WO 0130777	A	03-05-2001	AU BR CA CV WO EP HU JP NO SK TR US ZA	1515101 0014990 2388119 1382137 20021457 0130777 1244654 0203487 2003512466 20021959 7232002 200201128 6544993 2003166655 200203157	A A1 T A3 A1 A1 A2 T A A3 T2 B1 A1	08-05-2001 18-06-2002 03-05-2001 27-11-2002 17-07-2002 03-05-2001 02-10-2002 28-02-2003 02-04-2003 29-05-2002 10-09-2002 21-08-2002 08-04-2003 04-09-2003 10-04-2003
WO 9931071	Α	24-06-1999	AU WO	1760399 9931071		05-07-1999 24-06-1999
WO 9831674	A	23-07-1998	AT AU AU BR CDE DKA EE WO PU IL NO NZ PT SK TR	233247 735934 5862998 9806752 1127487 69811645 971901 2764 9900274 9831674 0971901 0001541 130659 2001508078 993301 336573 334561 971901 971901 95199 9901653	B2 A A B D1 T3 B1 A A1 A1 A2 A T A A1 T A	15-03-2003 19-07-2001 07-08-1998 14-03-2000 12-11-2003 03-04-2003 10-06-2003 29-08-2002 15-02-2000 23-07-1998 19-01-2000 28-05-2001 25-07-2002 19-06-2001 10-09-1999 27-10-2000 13-03-2000 31-07-2003 31-10-2003 10-12-1999 21-10-1999





Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9831674	A		US	6103718 A	15-08-2000
WO 9307146	Α	15-04-1993	AT	183745 T	15-09-1999
			ΑU	670544 B2	25-07-1996
			AU	2781592 A	03-05-1993
			CA	2117059 A1	15-04-1993
			DE	69229874 D1	30-09-1999
			DE	69229874 T2	09-12-1999
			DK	612321 T3	13-12-1999
			EP	0612321 A1	31-08-1994
•			ES	2105920 A1	16-10-1997
			ES	2135416 T3	01-11-1999
			FI	941567 A	06-04-1994
			GR	3030969 T3	30-11-1999
			HU	66969 A2	30-01-1995
			HU	9500113 A3	28-06-1995
			IL	103388 A	30-09-1997
			JP	3245165 B2	07-01-2002
			JΡ	7500321 T	12-01-1995
			KR	263494 B1	01-08-2000
			MX	9205794 A1	01-04-1993
			NO	941210 A	05-04-1994
			NZ	244660 A	26-05-1995
			PT	100938 A ,B	29-10-1993
			WO	9307146 A1	15-04-1993
			US	5716954 A	10-02-1998
			ZA	9207755 A	08-04-1994